When you think of COVID-19 vaccines, three companies come to mind: Pfizer, Johnson & Johnson, and Moderna. However, according to a recent FiercePharma article, there’s a new vaccine in town. On Monday, Novavax completed its emergency use authorization request with the FDA for its vaccine. The protein-based shot, dubbed NVX-CoV2373, is intended for people 18 and older, and has demonstrated 90% efficacy against symptomatic disease in large trials in the U.S. and Mexico.
Better Late Than Never: Novavax Submits COVID-19 Vaccine to FDA
The protein-based shot could still be used for boosters and in people under the age of 18.
Feb 4, 2022
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
